Consider this scenario: a potentially curative multiple sclerosis therapy is awaiting FDA approval. The pharmaceutical manufacturer has a lot at stake with this product—the company has spent decades discovering, researching and developing this medicine and put tremendous investment behind it. A million people in the U.S. are waiting anxiously for this drug to transform their lives and rid them of their disease.1 While…